Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Xanomeline Prodrug,Trospium Prodrug
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Terran Announces Develop of TerXT, Xanomeline &Trospium Prodrugs for Schizophrenia
Details : TerXT, is a small molecule combination of novel prodrugs of xanomeline and trospium designed to enable fixed-dose combinations for once-daily oral administration for the treatment for schizophrenia.
Product Name : TerXT
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2024
Lead Product(s) : Xanomeline Prodrug,Trospium Prodrug
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine,Inapplicable
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : N,N-dimethyltryptamine is a psychedelic tryptamine, non-selective agonist for 5HT2a receptor being developed as a therapy for patients with neurological & mental illness.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 02, 2023
Lead Product(s) : Dimethyltryptamine,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TR-01-XRR,TR-01-XRS,TR-01-XR,TR-01-IR
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Idazoxan in Healthy Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 14, 2023
Lead Product(s) : TR-01-XRR,TR-01-XRS,TR-01-XR,TR-01-IR
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Idazoxan,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Recipient : Pierre Fabre
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Terran obtains exclusive global development and commercialization rights for idazoxan hydrochloride, a selective alpha 2 receptor antagonist and a late-stage clinical therapeutic for the treatment of schizophrenia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 06, 2023
Lead Product(s) : Idazoxan,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Recipient : Pierre Fabre
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Deuruxolitinib phosphate,Inapplicable
Therapeutic Area : Dermatology
Study Phase : Phase III
Recipient : Concert Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Terran plans to quickly accelerate the development of these compounds as important complements to a growing pipeline of both early-stage and late-stage therapeutics and technologies in the CNS space.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 03, 2022
Lead Product(s) : Deuruxolitinib phosphate,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Recipient : Concert Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Tolebrutinib,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : old Sano
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Terran Biosciences Announces Licensing Deal with Sanofi for Two Late-Stage CNS Pipeline Assets
Details : Terran plans to quickly advance the development of the lead SAR442168 and other assets for neurological and psychiatric indications, which include several novel applications where there is a large unmet medical need.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 21, 2022
Lead Product(s) : Tolebrutinib,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : old Sano
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Dimethyltryptamine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Recipient : Blumentech S.L.
Deal Size : Undisclosed
Deal Type : Agreement
Details : Blumentech's patents further complement Terran's rapidly growing IP portfolio of over 150 patent applications in the psychedelic space, which includes patents on Terran's orally-active DMT compound, a product of Terran's robust medicinal chemistry drug d...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
April 13, 2022
Lead Product(s) : Dimethyltryptamine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Recipient : Blumentech S.L.
Deal Size : Undisclosed
Deal Type : Agreement